Skip to main content
. 2016 Jun 1;20(6):276–284. doi: 10.1089/gtmb.2016.0014

FIG. 1.

FIG. 1.

Results of commercial carrier tests and systematic analytics. (A) Donors identified as carriers with each testing panel or methodology are indicated with colored boxes. (B) The proportion of total dysfunctional variants identified as DCV or HLGD by NGS and the subportions detected by the combined commercial carrier testing panels. DCV, defined clinical variants; HLGD, high likelihood of gene dysfunction; NGS, next-generation sequencing. Color images available online at www.liebertpub.com/gtmb